We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Acid-Seeking "Warheads” Offer Safer, More Effective Cancer-Fighting Arsenal

By Biotechdaily staff writers
Posted on 11 Mar 2008
Researchers have recently reported on development of an anti-cancer "warhead” that targets the acidic signature of tumor cells in much the same way that heat-seeking missiles seek and destroy military targets that emit heat. These acid-seeking compounds are not toxic to healthy cells, and represent a new class of potentially safer, more effective anti-cancer drugs, according to the researchers.

The investigators' study is scheduled for the March 6, 2008, issue of The Journal of Physical Chemistry B. Scientists have long tried to develop anti-cancer drugs based on enediynes, a powerful class of natural, tumor-fighting agents derived from soil bacteria. However, as these substances kill both cancerous and healthy cells, their effectiveness as anti-cancer drugs is limited.

In the new study, Dr. Elfi Kraka and colleagues from the University of the Pacific (Stockton, CA, USA) described making unusual substances that become highly active only in the presence of low pH levels, or acidic environments. Because cancer cells have highly acidic environments in comparison to normal cells, compounds containing these substances--called dynemicin-amidines (DADs)--target and destroy tumor cells without affecting healthy cells, according to the researchers. The substances represent "the design of the first nontoxic enediyne antitumor drugs based on the DAD principle,” the report stated.


Related Links:
University of the Pacific

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Silver Member
Connectivity Solution
EKF Link
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
11 Mar 2008  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
11 Mar 2008  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
11 Mar 2008  |   BioResearch